Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mauss

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Journal of Viral Hepatitis|October 21, 2015
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countriesZ Younossi, A Brown, M Buti, et al.
HIV Medicine|January 26, 2018
Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?J Bischoff, S Mauss, C Cordes, et al.
Journal of Viral Hepatitis|February 18, 2010
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE studyT Witthoeft, D Hueppe, C John, et al.
European Journal of Medical Research|July 20, 2004
Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in GermanyMark Oette, R Kaiser, M Däumer, et al.
Journal of Viral Hepatitis|September 21, 2010
Estimating the likelihood of sustained virological response in chronic hepatitis C therapyS Mauss, D Hueppe, C John, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2017
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infectionM Cornberg, J Petersen, A Schober, et al.
European Journal of Medical Research|May 18, 2007
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patientsB Salzberger, M Däumer, P Gute, et al.
Zeitschrift Fur Gastroenterologie|April 14, 2015
[S3 guideline hepatitis C addendum]C Sarrazin, T Berg, P Buggisch, et al.
Zeitschrift Fur Gastroenterologie|January 7, 2012
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]C Sarrazin, T Berg, M Cornberg, et al.
Zeitschrift Fur Gastroenterologie|January 12, 2008
[Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units]D Hüppe, E Zehnter, S Mauss, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Viral Hepatitis|October 21, 2015
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countriesZ Younossi, A Brown, M Buti, et al.
HIV Medicine|January 26, 2018
Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?J Bischoff, S Mauss, C Cordes, et al.
Journal of Viral Hepatitis|February 18, 2010
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE studyT Witthoeft, D Hueppe, C John, et al.
European Journal of Medical Research|July 20, 2004
Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in GermanyMark Oette, R Kaiser, M Däumer, et al.
Journal of Viral Hepatitis|September 21, 2010
Estimating the likelihood of sustained virological response in chronic hepatitis C therapyS Mauss, D Hueppe, C John, et al.
Alimentary Pharmacology & Therapeutics|January 13, 2017
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infectionM Cornberg, J Petersen, A Schober, et al.
European Journal of Medical Research|May 18, 2007
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patientsB Salzberger, M Däumer, P Gute, et al.
Zeitschrift Fur Gastroenterologie|April 14, 2015
[S3 guideline hepatitis C addendum]C Sarrazin, T Berg, P Buggisch, et al.
Zeitschrift Fur Gastroenterologie|January 7, 2012
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]C Sarrazin, T Berg, M Cornberg, et al.
Zeitschrift Fur Gastroenterologie|January 12, 2008
[Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units]D Hüppe, E Zehnter, S Mauss, et al.
Pageof 9